-
Entrada Therapeutics announced positive initial data from their Phase 1/2 ELEVATE-44-201 study in DMD patients amenable to skipping exon 44.
Entrada Therapeutics, who received early funding from CureDuchenne to advance their Endosomal Escape Vehicle Platform,
-
Companies join forces to speed production of 1-time treatment for FSHD
Epicrispr Biotechnologies is partnering with Forge Biologics to support the development of EPI-321, Epicrispr’s one-time








